Sumitomo Dainippon Pharma to Expand Regenerative and Cellular Medicine CDMO Operations Jun. 8, 2022 Filed Under: Pharma Tagged With: CDMO, cellular medicine, regenerative medicine, Sumitomo Chemical, Sumitomo Dainippon PharmaSumitomo Dainippon Pharma Co. Ltd. (TYO:4506) and Sumitomo Chemical Co. Ltd. (TYO:4005) plan to expand their CDMO facilities for regenerative…... Please subscribe to read the full story. Subscribe Free Trial Related Articles:Sumitomo Chemical President Keiichi Iwata Lays out Plan to…Teijin Expands Health Care Operations for Bone and Joint…Mitsui Chemicals to Re-Enter Nucleic Acid Drug CDMO MarketMitsubishi Chemical to Produce Regenerative Medicine…Chemical and Material Companies Look to Take Pharmaceutical…Sumitomo Chemical Eyes Core Operating Income of 280B Yen in…